Evidence map›Paper›PMID 35883125›Full record

ArticleStem cell research & therapy2022

Integrin receptor-binding nanofibrous peptide hydrogel for combined mesenchymal stem cell therapy and nitric oxide delivery in renal ischemia/reperfusion injury.

Haniyeh Najafi, Samira Sadat Abolmaali, Reza Heidari, Hadi Valizadeh, Ali Mohammad Tamaddon, Negar Azarpira

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Effective and new technologies in kidney tissue engineering.Frontiers in bioengineering and biotechnology · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Haniyeh NajafiPharmaceutical Nanotechnology Department, Shiraz University of Medical Sciences, P. O. Box 71345-1583, Shiraz, Iran.
Samira Sadat AbolmaaliPharmaceutical Nanotechnology Department, Shiraz University of Medical Sciences, P. O. Box 71345-1583, Shiraz, Iran.
Reza HeidariPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, P. O. Box 71345-1583, Shiraz, Iran.
Hadi ValizadehDrug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Science, P. O. Box 51369-43738, Tabriz, Iran.
Ali Mohammad TamaddonPharmaceutical Nanotechnology Department, Shiraz University of Medical Sciences, P. O. Box 71345-1583, Shiraz, Iran. amtamadon@sums.ac.ir.
Negar AzarpiraTransplant Research Center, Shiraz University of Medical Sciences, Mohammad Rasoul-Allah Research Tower, P. O. Box 7193711351, Shiraz, Iran. azarpiran@sums.ac.ir.
Shiraz University of Medical Sciences · IRUniversity of Tabriz · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal-based therapy has been utilized as a practical approach in the treatment of renal ischemia/reperfusion (I/R) injury. However, low cell retention and survival in the ischemic site have remained challenging issues. To bridge this gap, the integrin receptor-binding RGD peptide-functionalized, s-nitroso-n-acetyl penicillamine (SNAP)-loaded hydrogel was used to transplant Wharton's jelly-mesenchymal stem cells (WJ-MSCs).

methodsApart from physicochemical and rheological characterizations that confirmed entangled interlocking β-sheets with nanofibrous morphology, real-time RT-PCR, ROS production, serum biomarker concentrations, and histopathological alterations were explored in a mouse model to assess the therapeutic efficacy of formulations in the treatment of renal I/R injury.

resultsThe RGD-functionalized Fmoc-diphenylalanine (Fmoc-FF + Fmoc-RGD) hydrogel supported the spread and proliferation of WJ-MSCs in vivo. Notably, intralesional injection of nitric oxide donor combined with the embedded WJ-MSCs caused superior recovery of renal I/R injury compared to free WJ-MSCs alone in terms of histopathological scores and renal function indices. Compared to the I/R control group, oxidative stress and inducible nitric oxide synthase (iNOS) expression biomarkers showed a significant decline, whereas endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) expression exhibited a significant increment, indicating regeneration of the injured endothelial tissue.

conclusionThe findings confirmed that the hydrogels containing WJ-MSCs and nitric oxide donors can promote the regeneration of renal I/R injuries by increasing angiogenic factors and cell engraftment.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationNanofibersReperfusion InjuryWharton JellyAnimalsDipeptidesHydrogelsIntegrinsIschemiaKidneyMiceNitric OxidePeptidesPhenylalanineVascular Endothelial Growth Factor ADipeptidesdiphenylalanineHydrogelsIntegrinsNitric OxidePeptidesPhenylalanineVascular Endothelial Growth Factor ADipeptide hydrogelMesenchymal stem cellsNitric oxide donorRenal ischemia/reperfusion injuryRGD peptide

Identifiers

PMID35883125
PMCPMC9327234
OpenAlexW4288053889

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.